

GUFIC BIOSCIENCES LIMITED

Regd. Office : 37, Kamala Bhavan II, S. Nityanand Road, Andheri (East), Mumbai - 400069
(CIN- L24100MH1984PLC033519)

Website - www.gufic.com, email - info@guficbio.com, Ph-022 67261000, Fax - 022 67261068

(Rs. in Lakhs except EPS)

Statement of Standalone Unaudited Financial Results for the Quarter Ended June 30, 2021

Sr. No.	Particulars	Quarter Ended			Year ended
		30-Jun-21	30-Jun-20	31-Mar-21	31-Mar-21
		Unaudited	Unaudited	Audited	Audited
1	INCOME				
a	Revenue from operations	25,075.77	6,079.65	13,192.92	48,769.87
b	Other Income	122.82	78.06	65.57	373.29
	Total Income	25,198.59	6,157.72	13,258.49	49,143.16
2	Expenses				
a	Cost of Materials consumed	11,261.58	3,354.00	4,957.41	21,345.17
b	Purchase of stock-in-trade	3,544.11	417.60	760.52	2,255.25
c	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(28.47)	(868.44)	820.32	1,428.79
d	Employee benefits expense	2,547.86	1,353.18	1,725.91	6,621.80
e	Finance Cost	120.94	337.74	287.20	1,363.33
f	Depreciation and amortisation expense	412.58	354.87	448.23	1,630.76
g	Other expenses	3,185.88	1,488.39	2,554.05	8,726.91
	Total Expenses	21,044.48	6,437.34	11,553.64	43,372.01
3	Total Profit / (Loss) before exceptional and tax (1-2)	4,154.11	(279.63)	1,704.85	5,771.15
4	Exceptional Items				
5	Total Profit / (Loss) Before Tax	4,154.11	(279.63)	1,704.85	5,771.15
6	Tax expense				
	Current Tax	1,056.00	-	805.01	1,719.82
	Deferred Tax	(22.59)	(136.32)	187.31	201.14
	Short/ (excess) Tax Provision of Earlier Years	-	-	(574.51)	(572.97)
	Total Tax Expenses	1,033.41	(136.32)	417.81	1,347.99
7	Net Profit/(Loss) for the period from continuing operations	3,120.70	(143.31)	1,287.04	4,423.16
8	Total Profit (Loss) for period	3,120.70	(143.31)	1,287.04	4,423.16
9	Other Comprehensive Income (OCI)				
	Items that will not be reclassified to profit and loss	-	-	38.51	38.51
	Less: Income tax relating to items that will not be reclassified to profit or (loss)	-	-	(11.41)	(11.41)
	Other Comprehensive Income / loss (net of taxes)	-	-	27.10	27.10
10	Total Comprehensive Income	3,120.70	(143.31)	1,314.14	4,450.26
11	Reserves				16,374.20
12	Details of Equity Share Capital				
	Paid-up equity share capital	969.45	969.45	969.45	969.45
	Face Value of equity share capital (Rs.)	1.00	1.00	1.00	1.00
13	Earning per equity share				
i	Basic earnings/(loss) per share from continuing and discontinued operations	3.22	(0.15)	1.33	4.56
ii	Diluted earnings/(loss) per share from continuing and discontinued operations	3.22	(0.15)	1.33	4.56

Notes:

- The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards), Rules, 2015 (Ind AS) as amended, prescribed under section 133 of companies Act, 2013, read with rules issued thereunder.
- The above Results for the quarter ended June 30, 2021 have been reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on August 11, 2021. The Statutory Auditors have carried out limited review of the results for quarter ended June 30, 2021.
- The Company's business activity falls within a single operating segment i.e. Pharmaceuticals.
- Pursuant to the sanction of the Scheme of Amalgamation of Gufic Lifesciences Private Limited ("Transferor Company") with the Company and their respective shareholders and creditors by the Hon'ble National Company Law Tribunal, Mumbai bench and Ahmedabad bench, the Board of Directors at its Meeting held on June 04, 2021 allotted 1,91,14,506 Equity Shares of Re. 1/- each of the Company to the Shareholders of the Transferor Company. The Company have received listing approval from National Stock Exchange of India Limited ("NSE") on July 22, 2021 and approval from BSE Limited ("BSE") is awaited. On receipt of listing approval from BSE, the Company shall apply for trading approval to BSE and NSE, within the stipulated timeframe.
- Previous year figures have been regrouped / reclassified, wherever necessary.

FOR GUFIC BIOSCIENCES LIMITED


Pooja V. JOSHI
CEO & WHOLE TIME DIRECTOR
DIN : 00001731

PLACE : MUMBAI
DATE : 11/08/2021





MITTAL AGARWAL & COMPANY

CHARTERED ACCOUNTANTS

Limited Review Report on the Unaudited Quarterly Financial Results of the Company Pursuant to Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended

Review Report to
The Board of Directors
Gufic Biosciences Limited

- 1) We have reviewed the accompanying statement of Unaudited Financial Results of **Gufic Biosciences Limited** (the "Company") for the quarter ended 30 June 2021 (the "Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- 2) This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.
- 3) We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit, and accordingly, we do not express an audit opinion.

Emphasis of Matter

- 4) The Board of Directors of the Company at its Board meeting held on 25 March 2019 approved the Scheme of Amalgamation of Gufic Lifesciences Private Limited ("Transferor Company") with the Company and their respective shareholders and creditors ("Scheme"), subject to sanction of the regulatory authorities. The Company has received approval from all the regulatory authorities to give effect to the said scheme of merger considering 01 January 2019 as date of merger. Further, to give accounting effect of the merger in the financial results, all the corresponding published figures for the quarter ended 30 June 2020 have been accordingly restated.

Attention is drawn to the fact that the comparative financial information to the extent it relates to the Transferor Company for corresponding quarter ended 30 June 2020 as reported in the financial results have been certified by the Management and were not subjected to our review.

Our opinion is not modified in respect of the above matter.

- 5) Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.





MITTAL AGARWAL & COMPANY


CHARTERED ACCOUNTANTS

- 6) The comparative financial information of the Company for corresponding quarter ended 30 June 2020 (excluding the comparative financial information for corresponding quarter ended 30 June 2020 to the extent it relates to the Transferor Company) was reviewed by the predecessor who expressed an unmodified opinion on the financial information for the quarter ended 30 June 2020 on 14 September 2020.

Place: Mumbai
Dated: 11/08/2021
UDIN: 21135505AAAADS9967



For Mittal Agarwal & Company
Chartered Accountants
(Firm Registration No. 131025W)


Piyush Agarwal
Partner
Membership No. 135505